We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Horizon Discovery Group Plc | LSE:HZD | London | Ordinary Share | GB00BK8FL363 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 184.50 | 184.50 | 185.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Horizon Discovery Group plc
Capital Markets Day Date Change to 5 March 2018
Cambridge, UK, 20 February 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global leader in gene editing and gene modulation technologies, announces that as a result of the leadership changes announced separately today, the Capital Markets Day in London for investors and sell-side analysts, will now take place on 5 March 2018 at Etc. Venues Fenchurch Street, 43/44 Crutched Friars, London, EC3N 2HH starting at 13:00 GMT / 8:00 EDT.
There will be a simultaneous live conference call and webcast for those unable to attend in person. The webcast, with the presentation slides, will be available at https://www.horizondiscovery.com/about-us/investor-relations and a recording will be made available shortly thereafter.
Please contact horizon@consilium-comms.com if you would like to attend.
ENDS
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plcIan Gilham, Chairman Richard Vellacott, Interim Chief Executive OfficerTel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)Michael Meade / Freddie Barnfield Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)Mary-Jane Elliott / Matthew Neal / Melissa GardinerTel: +44 (0) 20 3709 5701Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the tic
1 Year Horizon Discovery Chart |
1 Month Horizon Discovery Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions